TTC 352

Drug Profile

TTC 352

Alternative Names: TTC-352

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Illinois at Chicago
  • Class Antineoplastics; Small molecules; Thiophenes
  • Mechanism of Action Estrogen receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 04 Aug 2017 Chemical structure information added
  • 25 Jun 2017 TTC Oncology plans a phase I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule) (NCT03201913)
  • 02 Jun 2017 Pharmacodynamics and adverse events data from preclinical trials in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top